L. Adès, R. Itzykson, and P. Fenaux, Myelodysplastic syndromes, The Lancet, vol.383, issue.9936, pp.2239-2252, 2014.

D. A. Arber, A. Orazi, R. Hasserjian, J. Thiele, M. J. Borowitz et al., The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood, vol.127, issue.20, pp.2391-2405, 2016.

G. C. Bagby and G. Meyers, Bone Marrow Failure as a Risk Factor for Clonal Evolution: Prospects for Leukemia Prevention, Hematology, vol.2007, issue.1, pp.40-46, 2007.

A. G. Baikie, W. M. Court-brown, P. Jacobs, and J. S. Milne, CHROMOSOME STUDIES IN HUMAN LEUKÆMIA, The Lancet, vol.274, issue.7100, pp.425-428, 1959.

A. G. Baikie, P. A. Jacobs, J. A. Mcbride, and I. M. Tough, Cytogenetic Studies in Acute Leukaemia, BMJ, vol.1, issue.5239, pp.1564-1571, 1961.

G. Bardi, B. Johansson, N. Pandis, N. Mandahl, F. Mitelman et al., Cytogenetic analysis of 52 colorectal carcinomas--non-random aberration pattern and correlation with pathologic parameters, International Journal of Cancer, vol.55, issue.3, pp.422-428, 1993.

D. Barraco, S. Cerquozzi, C. A. Hanson, R. P. Ketterling, A. D. Pardanani et al., Cytogenetic findings in WHO-defined polycythaemia vera and their prognostic relevance, British Journal of Haematology, vol.182, issue.3, pp.437-440, 2017.

K. Becker, O. Fitzgerald, A. J. Green, M. Keogan, R. Newbury-ecob et al., Constitutional trisomy 8 and Behçet syndrome, American Journal of Medical Genetics Part A, vol.149A, issue.5, pp.982-986, 2009.

R. Bejar, K. Stevenson, O. Abdel-wahab, N. Galili, B. Nilsson et al., Clinical Effect of Point Mutations in Myelodysplastic Syndromes, New England Journal of Medicine, vol.364, issue.26, pp.2496-2506, 2011.

R. Bejar, K. E. Stevenson, B. Caughey, R. C. Lindsley, B. G. Mar et al., Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation, Journal of Clinical Oncology, vol.32, issue.25, pp.2691-2698, 2014.

J. M. Bennett, D. Catovsky, M. Daniel, G. Flandrin, D. A. Galton et al., Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group, British Journal of Haematology, vol.33, issue.4, pp.451-458, 1976.

J. M. Bennett, D. Catovsky, M. T. Daniel, G. Flandrin, D. A. Galton et al., Proposals for the classification of the myelodysplastic syndromes, British Journal of Haematology, vol.51, issue.2, pp.189-199, 1982.

N. A. Bérgamo, L. C. Veiga, S. Da, P. P. Reis, I. N. Nishimoto et al., Classic and Molecular Cytogenetic Analyses Reveal Chromosomal Gains and Losses Correlated with Survival in Head and Neck Cancer Patients, Clin. Cancer Res, vol.11, pp.621-631, 2005.

P. Bernasconi, C. Klersy, M. Boni, P. M. Cavigliano, I. Giardini et al., Does cytogenetic evolution have any prognostic relevance in myelodysplastic syndromes? A study on 153 patients from a single institution, Annals of Hematology, vol.89, issue.6, pp.545-551, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00516157

M. Block, L. O. Jacobson, and W. F. Bethard, Commentary on and reprint of Block M, Jacobson LO, Bethard WF, Preleukemic acute human leukemia, in Journal of the American Medical Association (1953) 152:1018?1028, Hematology, vol.152, pp.285-297, 2000.

T. Bochtler, S. Fröhling, and A. Krämer, Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia, Leukemia, vol.29, issue.6, pp.1243-1252, 2015.

J. Boultwood, S. Lewis, and J. S. Wainscoat, The 5q-syndrome, Blood, vol.84, issue.10, pp.3253-3260, 1994.

D. Bouscary, J. De-vos, M. Guesnu, F. Viguier, J. Melle et al., 101 Apoptosis and fas antigen (CD95) expression in myclodysplasia, Leukemia Research, vol.21, issue.1, p.S26, 1997.

D. Bouscary, J. De-vos, M. Guesnu, K. Jondeau, F. Viguier et al., Fas/Apo-1(CD95) expression and apoptosis in patients with myelodysplastic syndromes, Leukemia, vol.11, issue.6, pp.839-845, 1997.

M. Breccia, F. Biondo, R. Latagliata, I. Carmosino, F. Mandelli et al., Identification of risk factors in atypical chronic myeloid leukemia, Haematologica, vol.91, pp.1566-1568, 2006.

A. D. Chapelle, J. Schroder, and P. Vuopio, 8-trisomy in the bone marrow. Report of two cases, Clinical Genetics, vol.3, issue.6, pp.470-476, 2008.

C. Chen, Y. Liu, A. R. Rappaport, T. Kitzing, N. Schultz et al., MLL3 Is a Haploinsufficient 7q Tumor Suppressor in Acute Myeloid Leukemia, Cancer Cell, vol.25, issue.5, pp.652-665, 2014.

G. Chen, W. Zeng, A. Miyazato, E. Billings, J. P. Maciejewski et al., Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities, Blood, vol.104, issue.13, pp.4210-4218, 2004.

G. Chen, W. Zeng, A. Miyazato, E. Billings, J. P. Maciejewski et al., Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities, Blood, vol.104, issue.13, pp.4210-4218, 2004.

X. Chen, E. A. Eksioglu, J. Zhou, L. Zhang, J. Djeu et al., Induction of myelodysplasia by myeloid-derived suppressor cells, Journal of Clinical Investigation, vol.123, issue.11, pp.4595-4611, 2013.

C. R. Cogle, Incidence and Burden of the Myelodysplastic Syndromes, Current Hematologic Malignancy Reports, vol.10, issue.3, pp.272-281, 2015.

D. Wever, I. Cin, P. D. Fletcher, C. D. Mandahl, N. Mertens et al., Cytogenetic, Clinical, and Morphologic Correlations in 78 Cases of Fibromatosis: A Report from the CHAMP Study Group, Mod. Pathol, vol.13, pp.1080-1085, 2000.

M. G. Della-porta, E. Travaglino, E. Boveri, M. Ponzoni, L. Malcovati et al., Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes, Leukemia, vol.29, issue.1, pp.66-75, 2014.

T. Ernst, A. J. Chase, J. Score, C. E. Hidalgo-curtis, C. Bryant et al., Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders, Nature Genetics, vol.42, issue.8, pp.722-726, 2010.

P. Fenaux, P. Jonveaux, I. Quiquandon, J. L. Lai, J. M. Pignon et al., P53 gene mutations in acute myeloid leukemia with 17p monosomy, Blood, vol.78, issue.7, pp.1652-1657, 1991.

P. Fenaux, A. Giagounidis, D. Selleslag, O. Beyne-rauzy, G. Mufti et al., A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q, Blood, vol.118, issue.14, pp.3765-3776, 2011.

W. B. Fisher, S. A. Armentrout, R. Weisman, and R. C. Graham, "Preleukemia", Archives of Internal Medicine, vol.132, issue.2, p.226, 1973.

I. Gañán-gómez, Y. Wei, D. T. Starczynowski, S. Colla, H. Yang et al., Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes, Leukemia, vol.29, issue.7, pp.1458-1469, 2015.

N. Gangat, J. Strand, T. L. Lasho, C. M. Finke, R. A. Knudson et al., Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates, European Journal of Haematology, vol.80, issue.3, pp.197-200, 2008.

V. Gelsi-boyer, V. Trouplin, J. Adélaïde, J. Bonansea, N. Cervera et al., Mutations of polycomb-associated geneASXL1in myelodysplastic syndromes and chronic myelomonocytic leukaemia, British Journal of Haematology, vol.145, issue.6, pp.788-800, 2009.

F. I. Girtovitis, G. Ntaios, A. Papadopoulos, G. Ioannidis, and P. E. Makris, Defective Platelet Aggregation in Myelodysplastic Syndromes, Acta Haematologica, vol.118, issue.2, pp.117-122, 2007.

P. Greenberg, C. Cox, M. M. Lebeau, P. Fenaux, P. Morel et al., International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes, Blood, vol.89, issue.6, pp.2079-2088, 1997.

P. L. Greenberg, H. Tuechler, J. Schanz, G. Sanz, G. Garcia-manero et al., Revised International Prognostic Scoring System for Myelodysplastic Syndromes, Blood, vol.120, issue.12, pp.2454-2465, 2012.

P. L. Greenberg, R. M. Stone, A. Al-kali, S. K. Barta, R. Bejar et al., Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology, Journal of the National Comprehensive Cancer Network, vol.15, issue.1, pp.60-87, 2016.

P. Gupta, G. A. Niehans, S. C. Leroy, K. Gupta, V. A. Morrison et al., Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival, Leukemia, vol.13, issue.1, pp.44-53, 1999.

D. Haase, U. Germing, J. Schanz, M. Pfeilstöcker, T. Nösslinger et al., New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients, Blood, vol.110, issue.13, pp.4385-4395, 2007.

T. Haferlach, Y. Nagata, V. Grossmann, Y. Okuno, U. Bacher et al., Landscape of genetic lesions in 944 patients with myelodysplastic syndromes, Leukemia, vol.28, issue.2, pp.241-247, 2013.

R. Itzykson, O. Kosmider, A. Renneville, V. Gelsi-boyer, M. Meggendorfer et al., Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia, Journal of Clinical Oncology, vol.31, issue.19, pp.2428-2436, 2013.

R. Itzykson, M. Duchmann, N. Lucas, and E. Solary, CMML: Clinical and molecular aspects, International Journal of Hematology, vol.105, issue.6, pp.711-719, 2017.

J. Jonasson, G. Gahrton, J. Lindsten, C. Simonsson-lindemalm, and L. Zech, Trisomy 8 in Acute Myeloblastic Leukemia and Sideroachrestic Anemia, Blood, vol.43, issue.4, pp.557-563, 1974.

K. Kakosaiou, F. Panitsas, A. Daraki, M. Pagoni, P. Apostolou et al., ASXL1mutations in AML are associated with specific clinical and cytogenetic characteristics, Leukemia & Lymphoma, vol.59, issue.10, pp.2439-2446, 2018.

S. Y. Kim, J. K. Choi, Y. H. Cho, E. J. Chung, D. Paek et al., Chromosomal aberrations in workers exposed to low levels of benzene, Pharmacogenetics, vol.14, issue.7, pp.453-463, 2004.

A. Kode, J. S. Manavalan, I. Mosialou, G. Bhagat, C. V. Rathinam et al., Leukaemogenesis induced by an activating ?-catenin mutation in osteoblasts, Nature, vol.506, issue.7487, pp.240-244, 2014.

A. Kohlmann, V. Grossmann, C. Haferlach, B. Kazak, S. Schindela et al., Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 75% of Chronic Myelomonocytic Leukemia (CMML) by Detecting Frequent Alterations in TET2, RUNX1, CBL, and RAS., Blood, vol.114, issue.22, pp.417-417, 2009.

R. S. Komrokji, A. Kulasekararaj, N. H. Al-ali, S. Kordasti, E. Bart-smith et al., Autoimmune diseases and myelodysplastic syndromes, American Journal of Hematology, vol.91, issue.5, pp.E280-E283, 2016.

C. P. Kratz, C. M. Niemeyer, R. P. Castleberry, M. Cetin, E. Bergsträsser et al., The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease, Blood, vol.106, issue.6, pp.2183-2185, 2005.

M. S. Kumar, A. Narla, A. Nonami, A. Mullally, N. Dimitrova et al., Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q? syndrome, Blood, vol.118, pp.4666-4673, 2011.

J. L. Lai, C. Preudhomme, M. Zandecki, M. Flactif, M. Vanrumbeke et al., , 1995.

, Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations, Leukemia, vol.9, pp.370-381

S. J. Lee, J. K. Park, E. Y. Lee, S. H. Joo, K. C. Jung et al., Certain Autoimmune Manifestations Are Associated With Distinctive Karyotypes and Outcomes in Patients With Myelodysplastic Syndrome, Medicine, vol.95, issue.13, p.e3091, 2016.

R. C. Lindsley, B. G. Mar, E. Mazzola, P. V. Grauman, S. Shareef et al., Acute myeloid leukemia ontogeny is defined by distinct somatic mutations, Blood, vol.125, pp.1367-1376, 2015.

J. Maciejewski, C. Selleri, S. Anderson, and N. S. Young, Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro, Blood, vol.85, pp.3183-3190, 1995.

L. Malcovati, U. Germing, A. Kuendgen, M. G. Della-porta, C. Pascutto et al., Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes, Journal of Clinical Oncology, vol.25, issue.23, pp.3503-3510, 2007.

L. Malcovati, M. Karimi, E. Papaemmanuil, I. Ambaglio, M. Jädersten et al., SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts, Blood, vol.126, issue.2, pp.233-241, 2015.

M. Mallo, M. Del-rey, M. Ibáñez, M. J. Calasanz, L. Arenillas et al., Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations, Br. J. Haematol, vol.162, pp.74-86, 2013.

S. Martin, S. C. Baldock, A. T. Ghoneim, and J. A. Child, Defective neutrophil function and microbicidal mechanisms in the myelodysplastic disorders., Journal of Clinical Pathology, vol.36, issue.10, pp.1120-1128, 1983.

E. Maserati, F. Aprili, F. Vinante, F. Locatelli, G. Amendola et al., Trisomy 8 in myelodysplasia and acute leukemia is constitutional in 15-20% of cases, Genes, Chromosomes and Cancer, vol.33, issue.1, pp.93-97, 2001.

H. Medyouf, M. Mossner, J. Jann, F. Nolte, S. Raffel et al.,

, Myelodysplastic Cells in Patients Reprogram Mesenchymal Stromal Cells to Establish a Transplantable Stem Cell Niche Disease Unit, Cell Stem Cell, vol.14, pp.824-837

S. Merchav, A. Nagler, E. Sahar, and I. Tatarsky, Production of human pluripotent progenitor cell colony stimulating activity (CFU-GEMMCSA) in patients with myelodysplastic syndromes, Leukemia Research, vol.11, issue.3, pp.273-279, 1987.

N. Mikhailova, M. Sessarego, G. Fugazza, A. Caimo, S. D. Filippi et al., Cytogenetic abnormalities in patients with severe aplastic anemia, Haematologica, vol.81, pp.418-422, 1996.

R. Molist, M. Gerbault-seureau, X. Sastre-garau, B. Sigal-zafrani, B. Dutrillaux et al., Ductal breast carcinoma develops through different patterns of chromosomal evolution, Genes. Chromosomes Cancer, vol.43, pp.147-154, 2005.

M. Mossner, J. Jann, J. Wittig, F. Nolte, S. Fey et al., Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure, Blood, vol.128, issue.9, pp.1246-1259, 2016.

J. Mullenders, B. Aranda-orgilles, P. Lhoumaud, M. Keller, J. Pae et al., Cohesin loss alters adult hematopoietic stem cell homeostasis, leading to myeloproliferative neoplasms, Journal of Experimental Medicine, vol.212, issue.11, pp.1833-1850, 2015.

J. Nangalia and A. R. Green, Myeloproliferative neoplasms: from origins to outcomes, Blood, vol.130, pp.2475-2483, 2017.

T. A. Navas, M. Mohindru, M. Estes, J. Y. Ma, L. Sokol et al., Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors, Blood, vol.108, pp.4170-4177, 2006.

J. Neukirchen, M. Lauseker, B. Hildebrandt, A. Nolting, J. Kaivers et al., Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosis, Cancer, vol.123, issue.23, pp.4608-4616, 2017.

J. Nielsen and M. Wohlert, Chromosome abnormalities found among 34910 newborn children: results from a 13-year incidence study in ?rhus, Denmark, Human Genetics, vol.87, issue.1, pp.81-83, 1991.

L. Nilsson, I. Åstrand-grundström, I. Arvidsson, B. Jacobsson, E. Hellström-lindberg et al., Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level, Blood, vol.96, pp.2012-2021, 2000.

L. Nilsson, I. ?strand-grundstro?m, K. Anderson, I. Arvidsson, P. Hokland et al., Involvement and functional impairment of the CD34+CD38?Thy-1+ hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8, Blood, vol.100, issue.1, pp.259-267, 2002.

E. Papaemmanuil, M. Gerstung, L. Malcovati, S. Tauro, G. Gundem et al., Clinical and biological implications of driver mutations in myelodysplastic syndromes, Blood, vol.122, pp.3616-3627, 2013.

M. M. Patnaik, S. A. Parikh, C. A. Hanson, and A. Tefferi, Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review, British Journal of Haematology, vol.165, issue.3, pp.273-286, 2014.

M. M. Patnaik, R. Itzykson, T. L. Lasho, O. Kosmider, C. M. Finke et al., ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients, Leukemia, vol.28, issue.11, pp.2206-2212, 2014.

K. Paulsson and B. Johansson, Trisomy 8 as the sole chromosomal aberration in acute myeloid leukemia and myelodysplastic syndromes, Pathologie Biologie, vol.55, issue.1, pp.37-48, 2007.

K. Paulsson, T. Säll, T. Fioretos, F. Mitelman, and B. Johansson, The incidence of trisomy 8 as a sole chromosomal aberration in myeloid malignancies varies in relation to gender, age, prior iatrogenic genotoxic exposure, and morphology, Cancer Genetics and Cytogenetics, vol.130, issue.2, pp.160-165, 2001.

B. Pérez, O. Kosmider, B. Cassinat, A. Renneville, J. Lachenaud et al., Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia, British Journal of Haematology, vol.151, issue.5, pp.460-468, 2010.

M. J. Pettenati, N. Rao, M. Wofford, J. J. Shuster, D. J. Pullen et al., Presenting characteristics of trisomy 8 as the primary cytogenetic abnormality associated with childhood acute lymphoblastic leukemia, Cancer Genetics and Cytogenetics, vol.75, issue.1, pp.6-10, 1994.

U. Platzbecker, Treatment of MDS, Blood, vol.133, issue.10, pp.1096-1107, 2019.
URL : https://hal.archives-ouvertes.fr/hal-00549427

M. H. Raaijmakers, S. Mukherjee, S. Guo, S. Zhang, T. Kobayashi et al., Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia, Nature, vol.464, issue.7290, pp.852-857, 2010.

J. J. Rheingold, R. Kaufman, E. Adelson, and A. Lear, Smoldering Acute Leukemia, New England Journal of Medicine, vol.268, issue.15, pp.812-815, 1963.

G. W. Rhyasen, L. Bolanos, J. Fang, A. Jerez, M. Wunderlich et al., Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic Syndrome, Cancer Cell, vol.24, issue.1, pp.90-104, 2013.

I. Roberts and S. Izraeli, Haematopoietic development and leukaemia in Down syndrome, British Journal of Haematology, vol.167, issue.5, pp.587-599, 2014.

J. D. Rowley, R. K. Blaisdell, L. O. Jacobson, J. Mikuta, R. Byrne et al., Chromosome Studies in Preleukemia, Blood, vol.27, issue.6, pp.782-799, 1966.

M. I. Saarni and J. W. Linman, Preleukemia, The American Journal of Medicine, vol.55, issue.1, pp.38-48, 1973.

S. Saumell, L. Florensa, E. Luño, C. Sanzo, C. Cañizo et al., Prognostic value of trisomy 8 as a single anomaly and the influence of additional cytogenetic aberrations in primary myelodysplastic syndromes, British Journal of Haematology, vol.159, issue.3, pp.311-321, 2012.

S. Saumell, F. Solé, L. Arenillas, J. Montoro, D. Valcárcel et al., P-068 Trisomy 8 in de novo MDS, constitutional or not constitutional?, Leukemia Research, vol.37, p.S53, 2013.

S. Saumell, F. Solé, L. Arenillas, J. Montoro, D. Valcárcel et al., Trisomy 8, a Cytogenetic Abnormality in Myelodysplastic Syndromes, Is Constitutional or Not?, PLOS ONE, vol.10, issue.6, p.e0129375, 2015.

M. Sawanobori, S. Yamaguchi, M. Hasegawa, M. Inoue, K. Suzuki et al., Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes, Leukemia Research, vol.27, issue.7, pp.583-591, 2003.

J. Schanz, H. Tüchler, F. Solé, M. Mallo, E. Luño et al., New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge, Journal of Clinical Oncology, vol.30, issue.8, pp.820-829, 2012.

J. Schanz, N. Cevik, C. Fonatsch, F. Braulke, K. Shirneshan et al., Detailed analysis of clonal evolution and cytogenetic evolution patterns in patients with myelodysplastic syndromes (MDS) and related myeloid disorders, Blood Cancer Journal, vol.8, issue.3, 2018.

C. Schoch, A. Kohlmann, M. Dugas, W. Kern, S. Schnittger et al., Impact of trisomy 8 on expression of genes located on chromosome 8 in different AML subgroups, Genes, Chromosomes and Cancer, vol.45, issue.12, pp.1164-1168, 2006.

M. Sébert, R. S. Komrokji, M. A. Sekeres, T. Prebet, T. Cluzeau et al., Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine, Leukemia Research, vol.63, pp.72-77, 2017.

L. Seghezzi, E. Maserati, A. Minelli, C. Dellavecchia, P. Addis et al., Constitutional trisomy 8 as first mutation in multistep carcinogenesis: Clinical, cytogenetic, and molecular data on three cases, Genes, Chromosomes and Cancer, vol.17, issue.2, pp.94-101, 1996.

M. A. Sekeres, Epidemiology, Natural History, and Practice Patterns of Patients with Myelodysplastic Syndromes in 2010, Journal of the National Comprehensive Cancer Network, vol.9, issue.1, pp.57-63, 2011.

A. Shastri, B. Will, U. Steidl, and A. Verma, Stem and progenitor cell alterations in myelodysplastic syndromes, Blood, vol.129, issue.12, pp.1586-1594, 2017.

Y. Shen, H. Ma, D. Luo, J. Cai, J. Zou et al., High Incidence of Gastrointestinal Ulceration and Cytogenetic Aberration of Trisomy 8 as Typical Features of Behçet?s Disease Associated with Myelodysplastic Syndrome: A Series of 16 Consecutive Chinese Patients from the Shanghai Behçet?s Disease Database and Comparison with the Literature, BioMed Research International, vol.2018, pp.1-8, 2018.

E. M. Sloand, S. Kim, M. Fuhrer, A. M. Risitano, R. Nakamura et al., Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities, Blood, vol.100, issue.13, pp.4427-4432, 2002.

E. M. Sloand, S. Kim, M. Fuhrer, A. M. Risitano, R. Nakamura et al., Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities, Blood, vol.100, issue.13, pp.4427-4432, 2002.

E. M. Sloand, L. Mainwaring, M. Fuhrer, S. Ramkissoon, A. M. Risitano et al., Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome, Blood, vol.106, issue.3, pp.841-851, 2005.

E. M. Sloand, C. O. Wu, P. Greenberg, N. Young, and J. Barrett, Factors Affecting Response and Survival in Patients With Myelodysplasia Treated With Immunosuppressive Therapy, Journal of Clinical Oncology, vol.26, issue.15, pp.2505-2511, 2008.

E. M. Sloand, J. J. Melenhorst, Z. C. Tucker, L. Pfannes, J. M. Brenchley et al., T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy, Blood, vol.117, issue.9, pp.2691-2699, 2011.

M. T. Smith, L. Zhang, M. Jeng, Y. Wang, W. Guo et al., Hydroquinone, a benzene metabolite, increases the level of aneusomy of chromosomes 7 and 8 in human CD34-positive blood progenitor cells, Carcinogenesis, vol.21, issue.8, pp.1485-1490, 2000.

M. T. Smith, L. Zhang, M. Jeng, Y. Wang, W. Guo et al., Hydroquinone, a benzene metabolite, increases the level of aneusomy of chromosomes 7 and 8 in human CD34-positive blood progenitor cells, Carcinogenesis, vol.21, issue.8, pp.1485-1490, 2000.

E. Solary and R. Itzykson, How I treat chronic myelomonocytic leukemia, Blood, vol.130, issue.2, pp.126-136, 2017.

F. Sole, E. Luno, C. Sanzo, B. Espinet, G. F. Sanz et al., Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes, Haematologica, vol.90, pp.1168-1178, 2005.

A. S. Sperling, C. J. Gibson, and B. L. Ebert, The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia, Nature Reviews Cancer, vol.17, issue.1, pp.5-19, 2016.

J. L. Spivak, Myeloproliferative Neoplasms, New England Journal of Medicine, vol.376, issue.22, pp.2168-2181, 2017.

D. P. Steensma, R. Bejar, S. Jaiswal, R. C. Lindsley, M. A. Sekeres et al., Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes, Blood, vol.126, issue.1, pp.9-16, 2015.

A. Stoddart, A. A. Fernald, J. Wang, E. M. Davis, T. Karrison et al., Haploinsufficiency of del(5q) genes, Egr1 and Apc, cooperate with Tp53 loss to induce acute myeloid leukemia in mice, Blood, vol.123, issue.7, pp.1069-1078, 2014.

S. S. Strom, Y. Gu, S. K. Gruschkus, S. A. Pierce, and E. H. Estey, Risk factors of myelodysplastic syndromes: a case?control study, Leukemia, vol.19, issue.11, pp.1912-1918, 2005.

E. Such, J. Cervera, D. Costa, F. Sole, T. Vallespi et al., Cytogenetic risk stratification in chronic myelomonocytic leukemia, Haematologica, vol.96, issue.3, pp.375-383, 2010.

G. Tang, L. Zhang, B. Fu, J. Hu, X. Lu et al., Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution, American Journal of Hematology, vol.89, issue.8, pp.813-818, 2014.

G. Tang, L. Zhang, B. Fu, J. Hu, X. Lu et al., Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution, American Journal of Hematology, vol.89, issue.8, pp.813-818, 2014.

A. Tefferi, S. N. Thibodeau, and L. J. Solberg, Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphisms, Blood, vol.75, issue.9, pp.1770-1773, 1990.

S. Thota, A. D. Viny, H. Makishima, B. Spitzer, T. Radivoyevitch et al., Genetic alterations of the cohesin complex genes in myeloid malignancies, Blood, vol.124, issue.11, pp.1790-1798, 2014.

F. Traina, V. Visconte, P. Elson, A. Tabarroki, A. M. Jankowska et al., Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms, Leukemia, vol.28, issue.1, pp.78-87, 2013.

J. W. Vardiman, N. L. Harris, and R. D. Brunning, The World Health Organization (WHO) classification of the myeloid neoplasms, Blood, vol.100, issue.7, pp.2292-2302, 2002.

J. W. Vardiman, J. Thiele, D. A. Arber, R. D. Brunning, M. J. Borowitz et al., The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes, Blood, vol.114, issue.5, pp.937-951, 2009.

K. Virtaneva, F. A. Wright, S. M. Tanner, B. Yuan, W. J. Lemon et al., Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics, Proceedings of the National Academy of Sciences, vol.98, issue.3, pp.1124-1129, 2001.

J. Wang, X. Ai, R. P. Gale, Z. Xu, T. Qin et al., TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes, Leukemia Research, vol.37, issue.3, pp.305-311, 2013.

E. Wassie, C. Finke, N. Gangat, T. L. Lasho, A. Pardanani et al., A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients, British Journal of Haematology, vol.169, issue.1, pp.71-76, 2014.

E. A. Wassie, R. Itzykson, T. L. Lasho, O. Kosmider, C. M. Finke et al., Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study, American Journal of Hematology, vol.89, issue.12, pp.1111-1115, 2014.

K. Watanabe, Recent advances in the understanding of transient abnormal myelopoiesis in Down syndrome, Pediatrics International, vol.61, issue.3, pp.222-229, 2019.

Y. Wei, S. Dimicoli, C. Bueso-ramos, R. Chen, H. Yang et al., Toll-like receptor alterations in myelodysplastic syndrome, Leukemia, vol.27, issue.9, pp.1832-1840, 2013.

J. Welborn, Constitutional chromosome aberrations as pathogenetic events in hematologic malignancies, Cancer Genetics and Cytogenetics, vol.149, issue.2, pp.137-153, 2004.

N. Wesner, L. Drevon, A. Guedon, J. B. Fraison, S. Trad et al., OP0053 Inflammatory disorders associated with trisomy 8 myelodysplastic syndromes : french retrospective case control study, WEDNESDAY, 13 JUNE 2018, vol.0, pp.1-7, 2018.

B. Will, L. Zhou, T. O. Vogler, S. Ben-neriah, C. Schinke et al., Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations, Blood, vol.120, issue.10, pp.2076-2086, 2012.

P. S. Woll, U. Kjällquist, O. Chowdhury, H. Doolittle, D. C. Wedge et al., Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells In Vivo, Cancer Cell, vol.25, issue.6, pp.794-808, 2014.

S. R. Wolman, H. Gundacker, F. R. Appelbaum, and M. L. Slovak, Impact of trisomy 8 (+8) on clinical presentation, treatment response, and survival in acute myeloid leukemia: a Southwest Oncology Group study, Blood, vol.100, issue.1, pp.29-35, 2002.

L. Wu, L. Song, L. Xu, C. Chang, F. Xu et al., Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes, Tumor Biology, vol.37, issue.4, pp.4633-4640, 2015.

S. H. Swerdlow, E. Campo, N. L. Harris, E. S. Jaffa, S. A. Pileri et al., Myelodysplastic syndromes. The Lancet, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, vol.383, pp.2239-2252, 2014.

D. A. Arber, A. Orazi, R. Hasserjian, J. Thiele, M. J. Borowitz et al., The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood, vol.127, issue.20, pp.2391-2405, 2016.

D. Barraco, S. Cerquozzi, C. A. Hanson, R. P. Ketterling, A. D. Pardanani et al., Cytogenetic findings in WHO-defined polycythaemia vera and their prognostic relevance, British Journal of Haematology, vol.182, issue.3, pp.437-440, 2017.

T. Ernst, A. J. Chase, J. Score, C. E. Hidalgo-curtis, C. Bryant et al., Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders, Nature Genetics, vol.42, issue.8, pp.722-726, 2010.

L. Drevon, Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders, Nature Genetics, vol.42, pp.722-726, 2010.

P. Fenaux, A. Giagounidis, D. Selleslag, O. Beyne-rauzy, G. Mufti et al., A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q, Blood, vol.118, issue.14, pp.3765-3776, 2011.

N. Gangat, J. Strand, T. L. Lasho, C. M. Finke, R. A. Knudson et al., Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates, European Journal of Haematology, vol.80, issue.3, pp.197-200, 2008.

V. Gelsi-boyer, V. Trouplin, J. Adélaïde, J. Bonansea, N. Cervera et al., Mutations of polycomb-associated geneASXL1in myelodysplastic syndromes and chronic myelomonocytic leukaemia, British Journal of Haematology, vol.145, issue.6, pp.788-800, 2009.

P. Greenberg, C. Cox, M. M. Lebeau, P. Fenaux, P. Morel et al., International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes, Blood, vol.89, issue.6, pp.2079-2088, 1997.

P. L. Greenberg, H. Tuechler, J. Schanz, G. Sanz, G. Garcia-manero et al., Revised International Prognostic Scoring System for Myelodysplastic Syndromes, Blood, vol.120, issue.12, pp.2454-2465, 2012.

T. Haferlach, Y. Nagata, V. Grossmann, Y. Okuno, U. Bacher et al., Landscape of genetic lesions in 944 patients with myelodysplastic syndromes, Leukemia, vol.28, issue.2, pp.241-247, 2013.

R. Itzykson, O. Kosmider, A. Renneville, V. Gelsi-boyer, M. Meggendorfer et al., Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia, Journal of Clinical Oncology, vol.31, issue.19, pp.2428-2436, 2013.

A. Kohlmann, V. Grossmann, C. Haferlach, B. Kazak, S. Schindela et al., Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 75% of Chronic Myelomonocytic Leukemia (CMML) by Detecting Frequent Alterations in TET2, RUNX1, CBL, and RAS., Blood, vol.114, issue.22, pp.417-417, 2009.

C. P. Kratz, C. M. Niemeyer, B. D. Gelb, M. Tartaglia, and M. L. Loh, PTPN11 Mutational Spectrum in Juvenile Myelomonocytic Leukemia and Noonan Syndrome., Blood, vol.104, issue.11, pp.3417-3417, 2004.

N. Mikhailova, M. Sessarego, G. Fugazza, A. Caimo, S. D. Filippi et al., Cytogenetic abnormalities in patients with severe aplastic anemia, Haematologica, vol.81, pp.418-422, 1996.

F. Mitelman, B. Johansson, and F. Mertens, Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer, 2017.

J. Aranda-orgilles, B. Lhoumaud, P. Keller, M. Pae, J. Wang et al., Cohesin loss alters adult hematopoietic stem cell homeostasis, leading to myeloproliferative neoplasms, Journal of Experimental Medicine, vol.212, pp.1833-1850, 2015.

M. M. Patnaik, R. Itzykson, T. L. Lasho, O. Kosmider, C. M. Finke et al., ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients, Leukemia, vol.28, issue.11, pp.2206-2212, 2014.

K. Paulsson and B. Johansson, Trisomy 8 as the sole chromosomal aberration in acute myeloid leukemia and myelodysplastic syndromes, Pathologie Biologie, vol.55, issue.1, pp.37-48, 2007.

K. Paulsson, T. Fioretos, T. Mitelman, F. Johansson, B. ;-p-erez et al., The incidence of trisomy 8 as a sole chromosomal aberration in myeloid malignancies varies in relation to gender, age, prior iatrogenic genotoxic exposure, and morphology, Cancer Genetics and Cytogenetics, vol.130, pp.460-468, 2001.

S. Saumell, L. Florensa, E. Luño, C. Sanzo, C. Cañizo et al., Prognostic value of trisomy 8 as a single anomaly and the influence of additional cytogenetic aberrations in primary myelodysplastic syndromes, British Journal of Haematology, vol.159, issue.3, pp.311-321, 2012.

C. Schoch, A. Kohlmann, M. Dugas, W. Kern, S. Schnittger et al., Impact of trisomy 8 on expression of genes located on chromosome 8 in different AML subgroups, Genes, Chromosomes and Cancer, vol.45, issue.12, pp.1164-1168, 2006.

M. S-ebert, R. S. Komrokji, M. A. Sekeres, T. Prebet, T. Cluzeau et al., Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine, Leukemia Research, vol.63, pp.72-77, 2017.

E. M. Sloand, L. Mainwaring, M. Fuhrer, S. Ramkissoon, A. M. Risitano et al., Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome, Blood, vol.106, issue.3, pp.841-851, 2005.

F. Sol-e, B. Espinet, G. F. Sanz, J. Cervera, M. J. Calasanz et al., ) Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Español de Citogen etica Hematol ogica, British Journal of Haematology, vol.108, pp.346-356, 2000.

G. Tang, L. Zhang, B. Fu, J. Hu, X. Lu et al., Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution, American Journal of Hematology, vol.89, issue.8, pp.813-818, 2014.

S. Thota, A. D. Viny, H. Makishima, B. Spitzer, T. Radivoyevitch et al., Genetic alterations of the cohesin complex genes in myeloid malignancies, Blood, vol.124, issue.11, pp.1790-1798, 2014.

K. Virtaneva, F. A. Wright, S. M. Tanner, B. Yuan, W. J. Lemon et al., Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics, Proceedings of the National Academy of Sciences, vol.98, issue.3, pp.1124-1129, 2001.

K. Virtaneva, F. A. Wright, S. M. Tanner, B. Yuan, W. J. Lemon et al., Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics, Proceedings of the National Academy of Sciences, vol.98, issue.3, pp.1124-1129, 2001.

J. Wang, X. Ai, R. P. Gale, Z. Xu, T. Qin et al., TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes, Leukemia Research, vol.37, issue.3, pp.305-311, 2013.

E. A. Wassie, R. Itzykson, T. L. Lasho, O. Kosmider, C. M. Finke et al., Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study, American Journal of Hematology, vol.89, issue.12, pp.1111-1115, 2014.

E. Wassie, C. Finke, N. Gangat, T. L. Lasho, A. Pardanani et al., A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients, British Journal of Haematology, vol.169, issue.1, pp.71-76, 2014.

S. R. Wolman, H. Gundacker, F. R. Appelbaum, and M. L. Slovak, Impact of trisomy 8 (+8) on clinical presentation, treatment response, and survival in acute myeloid leukemia: a Southwest Oncology Group study, Blood, vol.100, issue.1, pp.29-35, 2002.

L. Wu, L. Song, L. Xu, C. Chang, F. Xu et al., Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes, Tumor Biology, vol.37, issue.4, pp.4633-4640, 2015.